-
England avoid seismic shock by beating Nepal in last-ball thriller
-
Karl defends Olympic men's parallel giant slalom crown
-
Colour and caution as banned kite-flying festival returns to Pakistan
-
England cling on to beat Nepal in last-ball thriller
-
UK foreign office to review pay-off to Epstein-linked US envoy
-
England's Arundell eager to learn from Springbok star Kolbe
-
Czech snowboard great Ledecka fails in bid for third straight Olympic gold
-
Expectation, then stunned silence as Vonn crashes out of Olympics
-
Storm-battered Portugal votes in presidential election run-off
-
Breezy Johnson wins Olympic downhill gold, Vonn crashes out
-
Vonn's Olympic dream cut short by downhill crash
-
French police arrest five over crypto-linked magistrate kidnapping
-
Late Jacks flurry propels England to 184-7 against Nepal
-
Vonn crashes out of Winter Olympics, ending medal dream
-
All-new Ioniq 3 coming in 2026
-
New Twingo e-tech is at the starting line
-
New Ypsilon and Ypsilon hf
-
The Cupra Raval will be launched in 2026
-
New id.Polo comes electric
-
Iran defies US threats to insist on right to enrich uranium
-
Seifert powers New Zealand to their record T20 World Cup chase
-
Naib's fifty lifts Afghanistan to 182-6 against New Zealand
-
Paul Thomas Anderson wins top director prize for 'One Battle After Another'
-
De Beers sale drags in diamond doldrums
-
NFL embraces fashion as league seeks new audiences
-
What's at stake for Indian agriculture in Trump's trade deal?
-
Real Madrid can wait - Siraj's dream night after late T20 call-up
-
Castle's monster night fuels Spurs, Rockets rally to beat Thunder
-
Japan votes in snow-hit snap polls as Takaichi eyes strong mandate
-
Pakistan's capital picks concrete over trees, angering residents
-
Berlin's crumbling 'Russian houses' trapped in bureaucratic limbo
-
Neglected killer: kala-azar disease surges in Kenya
-
Super Bowl set for Patriots-Seahawks showdown as politics swirl
-
Sengun shines as Rockets rally to beat NBA champion Thunder
-
Matsuyama grabs PGA Phoenix Open lead with Hisatsune one back
-
Washington Post CEO out after sweeping job cuts
-
Haiti's transitional council hands power to PM
-
N. Korea to hold party congress in February, first since 2021
-
Thailand votes after three leaders in two years
-
Swiss joy as Von Allmen wins first gold of Winter Olympics
-
George backs England to 'kick on' after Six Nations rout of Wales
-
Malinin upstaged as Japan keep pressure on USA in skating team event
-
Vail's golden comets Vonn and Shiffrin inspire those who follow
-
Veteran French politician loses culture post over Epstein links
-
Japan's Kimura wins Olympic snowboard big air gold
-
Arteta backs confident Gyokeres to hit 'highest level'
-
Hojlund the hero as Napoli snatch late win at Genoa
-
England's Arundell 'frustrated' despite hat-trick in Wales romp
-
Lollobrigida skates to first Italian gold of Winter Olympics on her birthday
-
Arundell hat-trick inspires England thrashing of Wales in Six Nations opener
Nobel winner's ingenious chemistry could lead to cancer breakthroughs
"All kinds of crazy things" is how Carolyn Bertozzi, a 2022 Nobel laureate, describes her life's work. Actually performing "chemistry in cells and in people."
When she started her research in 1997, the Stanford professor was aiming only to observe the evolution of certain molecules on the surface of cancer cells.
Today, thanks to her discoveries, at least two companies -- including one she co-founded -- are developing innovative cancer treatments.
The multitude of applications made possible by her findings are impressive: delivering treatments with extreme precision, understanding better how drugs act inside the body, visualizing certain bacteria, to name a few.
"I can't even really enumerate them. The vast majority of those applications I would never have foreseen," she told AFP in an interview.
The Nobel Prize committee recognized Bertozzi's pioneering advances on Wednesday, making her only the eighth woman to win the chemistry prize, at just 55 years old.
- Lego pieces -
Her journey began when she found she had a passion for organic chemistry, while taking pre-medicine courses at Harvard.
The subject is notoriously -- many say fiendishly -- difficult, but she credits an "amazing professor," the late David Evans, for bringing it to life -- and changing the course of her life.
"I said, forget the med school thing. I'm going to be a chemist," said Bertozzi, whose sister is a professor of applied mathematics, and father a retired professor of physics.
After completing her post-doctorate and joining the faculty at UC Berkeley, she wanted to take a closer look at glycans: complex carbohydrates, or sugars, located on the surface of cells, which "go through structural changes" when they become cancerous.
At the time, "there was no tool to image sugars, like in a microscope, for example," she said.
She had an idea that would require two chemical substances that fit together perfectly, like pieces of lego.
The first lego is fed to cells via a sugar. The cell metabolizes it and places it on the tip of the glycan. The second piece of lego, a fluorescent molecule, is injected into the body.
The two lego pieces click together, and voila: hidden glycans reveal themselves under a microscope.
This technique is inspired by "click chemistry" developed independently by Denmark's Morten Meldal and American Barry Sharpless -- Bertozzi's co-winners. But their discoveries relied on using copper as a catalyst, which is toxic to the body.
One of Bertozzi's great leaps was achieving the same type of ultra-efficient reaction without copper.
The other tour de force: making it all happen without wreaking havoc with other processes in the body.
"The beauty of it is that you can take the two Legos and click them together, even if they're surrounded by millions of other very similar plastic toys," she explained.
She coined the term "bioorthogonal chemistry," meaning a reaction that doesn't interfere with other biochemical processes. Perfecting the technique took 10 years.
- 'Cycle of science' -
Researchers are now leveraging these breakthroughs to develop cancer treatments.
Glycans on cancer cells "are able to hide the cancer cell from the immune system -- and so your body can't fight it, it can't see it," she explains.
Using bioorthogonal chemistry, "we made a new type of medicine, which basically acts like a lawnmower," says Bertozzi.
The first lego attaches to the cancer cell's surface, and the second, which clips onto it, is equipped with an enzyme that "mows off the sugars as if they're just grass, it cuts the grass and the sugars fall off," she says with a smile.
The drug is currently being tested in the early stages of a clinical trial.
Another company is seeking to use bioorthogonal chemistry to better target cancer treatment. The first lego piece is injected into a tumor, then a second, which carries the drug, attaches itself and acts only on its target.
"So that allows the oncologist to treat the tumor and kill the tumor without exposing the person's entire body to a toxic chemical," she says.
"What the future holds is hopefully an impact in human health," says Bertozzi. "But the people who decide that more so than myself, are the students and postdocs that join my lab."
Hundreds of them, current and former, filled her email box with messages of congratulations this morning.
"That really is the cycle of science -- it's being mentored and then mentoring" she adds. And "mentoring students gives you an opportunity to amplify the impact of your science."
T.Ward--AMWN